Free Access
Med Sci (Paris)
Volume 33, Novembre 2017
Les Cahiers de Myologie
Page(s) 58 - 60
Section Lu pour vous
Published online 15 November 2017
  1. Covaceuszach S, Bozzi M, Bigotti MG, et al. Structural flexibility of human α-dystroglycan. FEBS Open Bio 2017 ; 7 : 1064–1077. [CrossRef] [PubMed] [Google Scholar]
  2. Kanagawa M, Saito F, Kunz S, et al. Molecular recognition by LARGE is essential for expression of functional dystroglycan. Cell 2004 ; 117 : 953–964. [CrossRef] [PubMed] [Google Scholar]
  3. Sbardella D, Sciandra F, Gioia M, et al. α-dystroglycan is a potential target of matrix metalloproteinase MMP-2. Matrix Biol 2015 ; 41 : 2–7. [CrossRef] [PubMed] [Google Scholar]
  4. Brancaccio A, Adams JC. An evaluation of the evolution of the gene structure of dystroglycan. BMC Res Notes 2017 ; 10 : 19. [CrossRef] [PubMed] [Google Scholar]
  5. Le Guiner C, Montus M, Servais L, et al. Forelimb treatment in a large cohort of dystrophic dogs supports delivery of a recombinant AAV for exon skipping in Duchenne patients. Mol Ther 2014 ; 22 : 1923–1935. [CrossRef] [PubMed] [Google Scholar]
  6. Mack DL, Poulard K, Goddard MA, et al. Systemic AAV8-mediated gene therapy drives whole-body correction of myotubular myopathy in dogs. Mol Ther 2017 ; 25 : 839–854. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.